Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

NCT02057159 is registered in ClinicalTrials.gov with Immune Response BioPharma, Inc. as lead sponsor.

NCT NCT02057159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02057159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis
Lead sponsor
Immune Response BioPharma, Inc.
Phase
Phase 2/3
Overall status
Unknown status
Start date
March 9, 2020
Completion date
March 9, 2023
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, secondary progress multiple sclerosis